Incyte, TG's PI3K Inhibitors Show Safety Advantage In Indolent NHL

Data At ASH Show Strong Efficacy, Favorable Safety For Umbralisib, Parsaclisib

Neither TG's UNITY-NHL nor Incyte's CITADEL-203 study reported any fatal adverse events - a problem for which Gilead and Verastem's PI3K inhibitors carry boxed warnings.

Cancer
Incyte and TG Therapeutics presented Phase II data on their PI3K inhibitors at ASH. • Source: Shutterstock

Two new entrants into the PI3 kinase (PI3K) inhibitor space presented at the American Society of Hematology annual meeting may help reinvigorate a class of drugs for indolent non-Hodgkin’s lymphomas (NHL) whose members have often had to contend with unfavorable toxicity profiles. The two drugs – TG Therapeutics, Inc.’ umbralisib and Incyte Corporation’s parsaclisib – have shown high response rates and significantly better safety and tolerability than two of the PI3K inhibitors on the market, Gilead Sciences, Inc.’ Zydelig (idelalisib) and Verastem, Inc.’s Copiktra (duvelisib).

On 7 December, TG presented data from the Phase IIb UNITY-NHL study in marginal zone lymphoma (MZL), follicular lymphoma (FL)...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category